원진바이오테크놀로지
1 known investors
Onegene develops multi-modality drugs using enzyme-mediated protein-protein conjugation technology to create multispecific therapeutics for complex diseases. Its pipeline includes a tetra-specific treatment for non-alcoholic steatohepatitis (NASH) and a tri-specific approach for T-cell-based immune activation in oncology.
Investors · 1
Competitors · 2
by search overlap
Origene3 shared keywordsOriGene supplies research reagents including primary antibodies for flow cytometry, transfection kits (EZ-LNP and ProteanFect), RNAi gene silencing tools, and control solutions for life science laboratories. Its products serve researchers in molecular and cell biology.
One Biosciences3 shared keywordsOne Biosciences offers a single-cell analysis platform that resolves tumor samples (FFPE or frozen) cell by cell, producing single-cell maps and clinician-ready reports within two weeks. The AI-supported platform is validated across multiple tumor types and aimed at bringing single-cell data into clinical use.
Companies competing with 원진바이오테크놀로지 for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does 원진바이오테크놀로지 do?
- Onegene develops multi-modality drugs using enzyme-mediated protein-protein conjugation technology to create multispecific therapeutics for complex diseases. Its pipeline includes a tetra-specific treatment for non-alcoholic steatohepatitis (NASH) and a tri-specific approach for T-cell-based immune activation in oncology.
- Who are 원진바이오테크놀로지's investors?
- 원진바이오테크놀로지's investors include Solidus Investment.